Toujeo package insert. 1, JALAN KEMAJUAN, SEKSYEN 13, 46200 PETALING JAYA MALAYSIA.

Toujeo package insert Discontinue CONTRAVE if symptoms develop. Toujeo [package insert] Bridgewater, N. Toujeo dose (approximately 10-18%) may be needed to achieve target ranges for plasma glucose levels. 3 hours. 6-7. Toujeo is injected under the skin ( subcutaneous use, sc). Pen Type: Disposable Insulin Types: Long-acting Dose Delivery: 2-unit increments, up to 160 units at a Follow the Instructions for Use included in the package leaflet. It is important to perform a safety test when using a new pen for the first time. Other Glargine U-300, sold under the trade name Toujeo, is a long-acting insulin for subcutaneous injection, containing 300 units/mL of insulin glargine. J, Novo Nordisk, 2015 [Google Scholar] 15. ®NovoLog Mix 70/30 [package insert]. It is recommended for patients PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) – 1986 The medicine is dispensed with a doctor’s prescription only Toujeo Solution for subcutaneous injection in DoubleStar pen Active ingredient: Each pre-filled DoubleStar pen contains 300 units/ml of insulin glargine. Bridgewater, New Jersey. 1, There are three pens in a box of Toujeo Solostar. Toujeo™ is given • TOUJEO Max SoloStar is made to deliver the number of insulin units that your healthcare provider prescribed. , insulin strength, manufacturer, type, injection site, or method of administration) under close medical supervision with Toujeo can also be given together with other anti-hyperglycaemic medicinal products. Sanofi-Aventis. Never share a HUMULIN N pen, HUMULIN N KwikPen, or syringe between patients, even if the needle is changed. Re-use of 3 • Has not been studied in patients with a history of pancreatitis [see Warnings and Precautions (5. See dosage, • The dose counter of the TOUJEO SoloStar or TOUJEO Max SoloStar prefilled pen shows the number of units of TOUJEO to be injected and no conversion is required. 300 units/ml On 26 February 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a group of variation s to the terms of the marketing authorisation for the medicinal product Optisulin. 5 mL: 450 units: 80 units: 1 unit: 0024-5869-03: 3 pens/pack: Max SoloStar single-patient-use prefilled pen: 3 mL: 900 units: 160 units: 2 units: 0024-5871-02: 2 pens/pack: Needles are not included in the packs of TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use Toujeo SoloStar and Toujeo Max SoloStar are single-patient-use prefilled insulin pens. TOUJEO Max SoloStar contains 900 units of TOUJEO U-300. 1 mmol/L) or to the highest dose level (up to glipizide 20 mg and FARXIGA 10 mg) as tolerated by patients. 1. 5 mL single-patient-use prefilled pen Read this first Do not share your TOUJEO SoloStar pen with other people, even if the needle has been changed. I still can't get over why they didn't call it Threejeo Reply reply Lantus and Toujeo (insulin glargine 300 units/ml) are not bioequivalent and are not directly interchangeable. How to use Toujeo 4. insulin glargine-yfgn [package insert]. WARNINGS AND PRECAUTIONS Serious Warnings and Precautions Hypoglycemia is the most common adverse effect of insulin, including TOUJEO (see WARNINGS AND PRECAUTIONS, Endocrine and Metabolism, Important Safety Information for Toujeo U-300 (insulin glargine) injection SoloStar and Toujeo Max SoloStar. [see Warnings and Precautions (5. Toujeo™ contains the same active ingredient, insulin glargine, as LANTUS. Talk to packaging and label of the pen to ensure you take the correct insulin and avoid mix-ups with other insulins or products that you may have been prescribed. 1, JALAN KEMAJUAN, SEKSYEN 13, 46200 PETALING JAYA MALAYSIA. Toujeo must not be diluted. Ultra-rapid-acting . Short-acting insulins should be used to treat this condition. Food and Drug Administration (FDA) approved Toujeo ® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Pancreatitis: Postmarketing reports, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. There are two pens in a box of Toujeo Max Solostar. (1) -----DOSAGE AND ADMINISTRATION----- • Individualize dose based on type of diabetes, metabolic needs, blood glucose monitoringresults and glycemic control goal. If you use an injection pen, use only the injection pen that Package size: SoloStar disposable prefilled pen: 1. Sanofi. The Toujeo Max pen can provide up to 160 units of insulin at a time. What you need to know before you use Toujeo 3. 1 INDICATIONS AND USAGE . Toujeo 300 units/ml Solution for Injection in Pre-Filled Pen. 4, 4. 5 mg and were uptitrated over 18 weeks to optimal glycemic effect (FPG <110 mg/dL, <6. Uses. TOUJEO is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus. Food and Drug Administration labeling, package inserts, treatment Never share a TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pen between patients, even if the needle is changed. The safety and effectiveness of Toujeo™ has not been established in paediatric patients (under 18 years of age). Give an injection in the front of the thighs, in the upper arms or the front of the waist Learn about alternatives and more for Toujeo SoloStar and Toujeo Max SoloStar (insulin glargine), which are prescription injections for diabetes. The results Toujeo. insulin glargine . If you do not do this, your full dose will not be delivered. Note: Multiple pictures are displayed for those medicines available in different strengths, marketed under different brand names and for medicines manufactured by different pharmaceutical companies. (2017). What Toujeo is and what it is used for Toujeo contains insulin called “insulin glargine”. • TOUJEO occur. 15-17 minutes. Toujeo Max SoloStar has Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Toujeo have also been included in the summary of product characteristics and the package leaflet. The most common concentration ordered to control blood glucose, regardless of its pharmacokinetic profile, is U-100 (100 units/mL) (). Toujeo ® is not the insulin of choice for the treatment of diabetic ketoacidosis. Heise T, Hövelmann U, Nosek L, et al. Interactions. Lispro-aabc (Lyumjev) U100, U200. I still can't get over why they didn't call it Threejeo Reply reply 3 . In 2014, it was estimated that 9% of adults aged 18 and above had diabetes worldwide, 90% being type 2 diabetes (World Health Organization [WHO], 2015). FULL PRESCRIBING INFORMATION . If pioglitazone is used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure, patients should be observed for signs and symptoms of heart failure, weight gain and oedema Toujeo may have additional side effects including swelling, weight gain, low potassium, and injection site reactions which may include change in fat tissue, skin thickening, redness, swelling, and itching. JAMA. The safety and effectiveness of Toujeo have not been established in paediatric patients (under 6 years of age). To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying their pen; otherwise, they may not get the correct amount of As the prevalence of diabetes mellitus increases, so too does the number of available treatment modalities. This brand name is authorized in Austria, Australia , Medication package inserts. If you see particles, do not The NDC Packaged Code 0024-5869-03 is assigned to a package of 3 syringe in 1 carton / 1. 5 ml of TOUJEO safely and effectively. Bridgewater (NJ): Sanofi-Aventis U. 2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen Changes in Insulin Regimen Including Changes to Administration Site Changes in an insulin Never share a TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pen between patients, even if the needle is changed. at the beginning of Q2 2015. 2017;318(1):33-44. Novo Nordisk. Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter. Indianapolis, IN: Lilly USA LLC; July 2021. Insulin labels must a more rapid onset of action than subcutaneously administered insulin, requiring more close monitoring for hypoglycemia. 2 17 PATIENT COUNSELING INFORMATION * Sections or subsections omitted from the full prescribing information are not listed. Phone No : 03-76510800. Toujeo Max Solostar warnings . If this happens, you should check TOUJEO- insulin glargine injection, Package size; SoloStar single-patient-use prefilled pen: 1. Morgantown, West Virginia. Learn more about Toujeo Toujeo [package insert]. Toujeo Solostar is not suitable for the treatment of diabetic ketoacidosis. Bridgewater, NJ: sanofi-aventis US LLC; March 2023. Switch between insulin glargine 100 units/ml and Toujeo: Insulin glargine 100 units/ml and Toujeo are not bioequivalent and are not directly interchangeable. Package insert / product label Generic name: insulin glargine Dosage form: injection, solution Drug class: Insulin J Code (medical billing code): J1815 (Per 5 units, injection) Medically reviewed by Drugs. TOUJEO® MAX SOLOSTAR the packaging is damaged, return it to your pharmacist for disposal. Toujeo® SoloStar® Welcome Pack For Diabetes MAT-MY-2200281 (V1. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023. Last updated on Aug 29, 2023. Pen sharing poses a risk for transmission of blood-borne pathogens. Important information during the initial weeks when prescribed Toujeo® Insulin glargine 300 units/ml (Toujeo®) and insulin glargine Never share a NOVOLIN N FlexPen or syringe between patients, even if the needle is changed. PACKAGE LEAFLET. The recommended starting dosage of MARINOL is 5 mg/m 2, orally administered 1 to 3 hours prior to the administration of chemotherapy and then every 2 to 4 hours after chemotherapy, for a total of 4 to 6 doses per day. Never share a VICTOZA pen between patients, even if the needle is changed . Discontinue promptly if pancreatitis is suspected. 2015. Insulin glargine no longer has a pregnancy category, and its package inserts simply state that there are “no well-controlled clinical studies in pregnant women” (24,25). Do not restart if pancreatitis is confirmed (). Talk to For more information about using Toujeo, see the package leaflet or contact your doctor or pharmacist. In senior adults treated with basal insulin, switching to Sanofi's toujeo halved hypoglycemia risk. Toujeo™ must not be mixed with any other insulin products. Advanced Search Citation Search. It delivers doses in 1-unit increments and can deliver up to 80 units in a single injection. TOUJEO SoloStar or TOUJEO Max SoloStar disposable prefilled pens must never be shared between patients, even if the needle is changed. Toujeo[Package Insert]. Never share a TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pen between patients, even if the needle is changed. Type. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying their pen; otherwise, they may not get the correct amount of The purpose of this article is to educate nurse practitioners about the role of Toujeo®, insulin glargine U-300 (Gla-300), which is a new option for the treatment of diabetes mellitus. The prolonged effect of insulin glargine may delay recovery from hypoglycemia. What does Toujeo Max SoloStar look like? Before injecting Toujeo. Toujeo can also be given together with other anti-hyperglycaemic medicinal products. The device delivers insulin in 2-unit increments up to160 units at a time Features. It is given subcutaneously and has a recommended starting dose of 0. 5 ml 3 pre-filled pens sulin degludec, Toujeo, Tresiba, and ultra-long-acting insulin. 5 mL disposable prefilled pen Read this first Do not share your TOUJEO SoloStar pen with other people, even if the needle has been changed. 1 Important Administration Instructions. 25, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that the U. ; FARXIGA ® (dapagliflozin) [package insert]. Toujeo must not be mixed with any other insulin products. 7. Explore diabetes Explore obesity Explore rare bleeding disorders Explore This website contains information and package inserts for products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Insulin Pharmacokinetic and Pharmacodynamic Properties. Lot: 123XY EXP: DD/MM/YYYY Use only in this pen or 1 TOUJEO is a long- acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus (1) Limitations of Use: Not recommended for treating diabetic ketoacidosis. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Toujeo (insulin glargine injection) U-300 July 31, 2019 S-014 October 3, 2019 Please also refer your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lantus, Apidra, and Toujeo. FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE . Multi-ingredient medications may also be listed when applicable. %PDF-1. Food and Drug Administration FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes [press release]. An anonymous, three-question survey was administered to third year medical students (N=34) from two medical schools to assess how well they had been educated about the evidence-based origin, purpose, and implications of the package insert. , insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood Insulin is packaged in various ways that can be broadly classified as vials, prefilled pens, and cartridges and allow insulin to be administered via different modalities (Supplementary Table S1). 2 Initiation of LEVEMIR Therapy . 1 ml of solution contains 300 units of insulin glargine. Each SoloStar pen delivers 1–80 units in steps of 1 unit. reduce the risk of hypoglycaemia. It is recommended for patients Toujeo - Get up-to-date information on Toujeo side effects, uses, dosage, overdose, pregnancy, alcohol and more. 6. Select Long-Acting Insulin Products . Perform a safety test as described in step 3 of the instructions for use. Updated November 2019. Avoid medication errors by using only the medicine your doctor prescribes. Mixing changes the time/action profile of Toujeo and causes precipitation. Skip to content. 2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen Changes in Insulin Regimen Including Changes to Administration Site Changes in an insulin Toujeo (insulin glargine injection) U-300 is indicated to improve glycemic control in pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. ; Visually inspect the Insulin Glargine, U-300 solution for particulate matter and discoloration prior to administration and only use if the solution is clear and colorless with no visible particles. 2,3 dStoring without the needle attached helps prevent leaking, blocking of the needle, and air from entering the pen. Lantus [package insert]. 4)]. This dose reduction will lower the likelihood of hypoglycemia [see Warnings and Precautions (5. 20,22 Studies that included only patients with T2DM showed that concentrated U-300 demontrated no difference in A1C reductions compared with U-100 and no difference in rates of overall hypoglycemia, with the exception of Toujeo Max SoloStar Images. Toujeo must not be drawn from the cartridge of the Toujeo SoloStar pre-filled pen into a syringe or severe overdose can result (see section 4. Twice TOUJEO ®SoloStar (Too-Jay-o) (insulin glargine injection) 1. (1) Limitations of Use: Not TOUJEO is a long-acting insulin for adults and pediatric patients with diabetes mellitus. x. 15. Glargine is a human insulin analog and differs from regular human insulin Toujeo - Get up-to-date information on Toujeo side effects, uses, dosage, overdose, pregnancy, alcohol and more. DailyMed. Bridgewater: Sanofi US, Inc. Duration. The recommended starting dose of LEVEMIR in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Indianapolis, IN: Eli TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pens must never be shared between patients, even if the needle is changed. Use HUMALOG in accordance with the insulin pump system’s instructions for use. When switching from insulin glargine 100 units/ml to Toujeo, this can be done on a unit-to-unit basis, but 2. Glargine is a human insulin analog and differs from regular 1. In clinical trials both were found comparable to Lantus (insulin glargine) and Levemir (insulin detemir [rDNA origin] injection), with regard to lowering A1c; both may also be associated with lower Releuko package insert / prescribing information for healthcare professionals. Please be aware that Cepheid does not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration The recommended starting dose of Toujeo® in patients with type 2 diabetes who are not currently treated with insulin is 0. When left unrefrigerated, the pen should be stored with the cap on to prevent the degradation of the insulin. Fiasp [package insert]. Toujeo SoloStar sisältää 300 yksikköä/ml glargininsuliinia 1,5 millilitran kertakäyttöisessä esitäytetyssä Tresiba [package insert] Plainsboro, N. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Toujeo ® 300 units/ml Read the Instructions for Use that come with the package leaflet. 2)]. Follow the Instructions for Use included in the package leaflet. Tresiba [package insert]. The dose regimen (dose and timing) should be adjusted according to Toujeo™ exhibits a more constant and prolonged glucose-lowering profile than LANTUS. Canada Post has resumed normal shipping. Food and Drug Administration (FDA) on February 25, 2015, and is currently pending Toujeo Max SoloStar. We also refer to our letter dated September 4, 2019, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe Toujeo [package insert]. ¶ Patients on metformin ≥1500 mg per day were randomized following a 2-week placebo lead-in period to glipizide 5 mg or dapagliflozin 2. Order from PharmaServe for a long-acting insulin that helps regulate blood sugar levels in adults with diabetes, providing a more stable and consistent insulin release. Once in use, the device must be kept at room temperature and should not be refrigerated. 16. The increasing prevalence of diabetes is a global health concern. This medicine is not right for everyone. Read all of this leaflet carefully before you start using this medicine because it contains important information for you. Toujeo is expected to be available in the U. See Important Safety Information. Each SoloStar prefilled pen contains 1. Toujeo Max SoloStar (insulin glargine U-300) is a long-acting, concentrated insulin analog delivered in a disposable pen with a 900-unit capacity. 5 ml 1 pre-filled pen EU/1/00/133/034 Toujeo 300 units/ml Solution for injection Subcutaneous use cartridge (glass) in pre-filled pen (SoloStar) 1. 2 Nausea and Vomiting Associated with Cancer Chemotherapy in Adult Patients Who Failed Conventional Antiemetics. 4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE). Toujeo Max Solostar contraindications. Updated July 2021. Glargine U-300, sold under the trade name Toujeo, is a long-acting insulin for subcutaneous injection, containing 300 units/mL of insulin glargine. Important Safety Information Contraindications Toujeo is contraindicated during episodes of hypoglycemia and in patients Somos la empresa líder de la industria farmacéutica en Europa y en Latino America, y miembros activos de la CIF en Chile. U. Insulin glargine is a man-made product References: FARXIGA ® (dapagliflozin) [package insert]. 4. Insulin labels must always be checked before each injection to avoid medication errors between Toujeo and other insulins (see Section 4. Toujeo (insulin glargine 300 units/mL) and Tresiba (insulin degludec 100 units/mL or 200 units/mL). During the first weeks Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Toujeo have also been included in the summary of product characteristics and the package leaflet. 1 million people (9. Side effects reported with Toujeo are carefully Toujeo, Toujeo Max 1-4 No pronounced peak Up to 24 36 (Toujeo/Toujeo Max) Detemir Levemir Degludec Tresiba Up to 42 Bolus Basal APIDRA® [package insert]. Toujeo (package insert). 13. See dosage, administration, warnings, adverse reactions, drug interactions and more in the full prescribing TOUJEO is indicated to improve glycemic control in adults and pediatric patients 6 years of age and older with diabetes mellitus. Each mL of TOUJEO contains 300 units of insulin glargine dissolved Toujeo is a once-daily basal insulin for the treatment of diabetes mellitus in adults. Dosing of U-100 generally ranges from 0. ÀÉÞù¸œ Toujeo ® [package insert]. Toujeo™ can be used in elderly patients, in patients with renal impairment and in patients with hepatic impairment. A new sterile needle must be attached before each injection. In this case, Toujeo or Toujeo Max may be an option to consider. 2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen Changes in Insulin Regimen Including Changes to Administration Site Changes in an insulin Once-daily TOUJEO (insulin glargine 300 units/mL) to once-daily Insulin Glargine (100 units/mL), the recommended starting Insulin Glargine dosage is 80% of the TOUJEO dosage that is being discontinued. An intravenous, short-acting insulin is the pre ferred treatment. Humulin N [package insert]. The onset of action of TOUJEO develops over 6 hours following an injection. See dosage, administration, warnings, adverse reactions, and more in the full prescribing infor TOUJEO is a long-acting human insulin analog for adults with diabetes mellitus. Conoce más sobre nosotros y nuestras áreas terapéuticas. Date Article; Mar 27, 2018: Approval FDA Approves Toujeo (insulin glargine) Max SoloStar: Feb 25, 2015 : Approval Sanofi Receives FDA Approval of Once-Daily Basal 3 • Has not been studied in patients with a history of pancreatitis [see Warnings and Precautions (5. Indianapolis, IN: Lilly USA LLC; 2015 Novolog® [package insert]. Toujeo ® is TOUJEO SoloStar or TOUJEO Max SoloStar disposable prefilled pens must never be shared between patients, even if the needle is changed. Toujeo™ must not be diluted. Hypoglycemia: Adult patients taking an insulin secretagogue or insulin may have an increased 2. • Inject TOUJEO TOUJEO were required to achieve similar levels of glucose control compared to LANTUS in clinical trials (see CLINICAL TRIALS). 5, 0. Type 1 Diabetes . Toujeo [package insert]. Updated December 2019. Toujeo is a replacement insulin that is very similar to the insulin made by the body. 6). Novo Nordisk A/S; 2017 Toujeo Max [package insert]. Holder : SANOFI-AVENTIS (MALAYSIA) SDN. 5 mL: 450 units: 80 units: 1 unit: 0024-5869-03: 3 pens/pack: Max SoloStar single-patient-use prefilled pen: 3 mL: 900 units: 160 units: 2 units: 0024-5871-02: 2 pens/pack: Needles are not included in the packs of TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use Toujeo® units/ml in su li ng lA RGi ne Use only in this pen or seve re o verdose can result. Explore diabetes Explore obesity Explore rare bleeding disorders Explore growth-related disorders Explore rare renal disorders Never share a HUMALOG prefilled pen, cartridge, reusable pen compatible with Lilly 3 mL cartridges, or syringe between patients, even if the needle is changed. Search term. For current labeling patients Never share a LANTUS SoloStar prefilled pen, insulin syringe, or needle between patients, even if the needle is changed. This label may not be the latest approved by FDA. Then remove the inner needle cap and throw it in the trash. Toujeo is for subcutaneous use only and should be administered by However, the package inserts for each of the insulin pens explicitly state that patients should not draw up insulin out of the pens using a syringe (3,6,7). Once-daily NPH insulin to once-daily Insulin Glargine, the recommended starting Insulin Glargine dosage is the same as the dosage of NPH that is being Abstract Purpose The purpose of this article is to educate nurse practitioners about the role of Toujeo®, insulin glargine U-300 (Gla-300), which is a new option for the treatment of diabetes melli Skip to Article Content; Skip to Article Information; Search within. Faster aspart The FDA on February 25, 2015, approved the basal insulin Toujeo, which Sanofi sees as a successor to Lantus to treat patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM). This product is TOUJEO (insulin glargine). 7 %âãÏÓ 1012 0 obj >stream hÞÔYmOä6 þ+þ ªPü ;Ò ØRP{ôÄÒ£:ćÍA¤}A»{mù÷ qlÇÎ&»°ô®âÃl Ïx ¶ÇOžÌJe %2ç„1 WA ˆÌ%‘TÃU ¥ð9'y^ÀU -ÑÎ Bc{A8“ Дp¡ Ü0" šhN„–à í t¦%QLr¸Q$ š5¸µþ5øÕ { ¢ )ȇ Ùàh/;+' A|W_áç ìgƒKPü»Ÿ «Ù Ü~ œ æ÷¾ H!Àðòð0; ÏV ·ý%8†ÖìËhp ¼6A£ªœŒ—7·‡‡`úûb\. e of medicine, prescribers often minimize, overlook, or misunderstand its importance, suggesting a gap in their training. Toujeo is not for the treatment of diabetic ketoacidosis; It is not known if Toujeo is safe and effective in children under 6 years of age ; Important Safety Manage your diabetes with Toujeo (insulin glargine injection). Package leaflet: information for the user. Holder Address : UNIT TB-18-1, LEVEL 18, TOWER B, PLAZA 33, NO. Mylan Pharmaceuticals. TOUJEO is a long-acting human insulin analog for diabetes mellitus. the time/action profile of Toujeo and causes precipitation. Two new long-acting insulin products were recently approved by the FDA. ; 2015. Table 1. Possible side effects 5. 57 minutes. 2 U/kg once daily. Side effects reported with Toujeo are carefully There are three pens in a box of Toujeo Solostar. The marketing authorisation holder for this medicinal product is Sanofi-Aventis Deutschland GmbH. 1, Tresiba [package insert]. Whether the ratio is expressed somewhere in the literature to an actual average variability I am not sure but at least that is some reference to a unit per unit that more Toujeo may be needed than Lantus. Plainsboro, NJ: Novo Nordisk Inc; July 2022. 25, ||P<0. Toujeo (insulin glargine 300 units/mL) is a basal insulin for once-daily subcutaneous administration at any time of the day, preferably at the same time every day. You may give other people a serious infection, or get a serious infection from them. s. Indianapolis (IN): Eli Lilly and Company; 2013 Nov. Package insert / product label Generic name: insulin glargine Dosage form: injection, solution Drug class: Insulin J Code (medical billing code): J1815 (Per 5 units, injection) Medically reviewed Toujeo Prescribing Information. Toujeo package insert says when switching from Lantas to Toujeo that more units may be required. It is available in two prefilled pens and should be injected once a day at the same Before using Toujeo SoloStar pre-filled pen or Toujeo DoubleStar pre-filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6. Winthrop U. Dk2880 Bagsvaerd, Denmark. The active substance in Toujeo, insulin glargine, is (See the respective package inserts for complete VZIG and IG prescribing information. Toujeo SoloStar and Toujeo Max SoloStar are single-patient-use prefilled insulin pens. Novo Nordisk A/S; 2015 JAMA 2017;318(1):45-56 üIF CONVERTING TOTOUJEO, CONVERT UNIT-PER-UNIT, üIF CONVERTING FROM TOUJEO, ADMINISTER 80% OF DOSE üADJUST DOSE IN 2-UNIT INCREMENTS (MAX SOLOSTAR) Tresiba U-200 Toujeo U-300. Read the instructions for use that come with the package insert. - When switching from Toujeo to insulin glargine 100 units/ml, the dose should be reduced (approximately by 20%) to . Sanofi-Aventis; 2015 Tresiba [Package Insert]. If pioglitazone is used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure, patients should be observed for signs and symptoms of heart failure, weight gain and oedema Toujeo contains 300 units of insulin glargine per milliliter (mL), which is 3 times stronger than brands that contain 100 units per mL. Below package inserts are available for further reading: Title Information Source Document Type ; TOUJEO Solution for injection: European Medicines Agency (EU) MPI, EU: SmPC Medicine classification . 0) | DOP: May 2022 This item is intended for people with diabetes who have been prescribed Toujeo® SoloStar®. Glargine is a human insulin analog and differs from regular human insulin cOpened (in-use) SoloSTAR ® devices must be discarded 4 weeks (Lantus ®) or 8 weeks (Toujeo ®) after being opened. , insulin strength, manufacturer, type, injection site, or method of administration) under close medical supervision with Toujeo Prescribing Information. With Toujeo SoloStar pre-filled pen, a dose of 1-80 units per injection, in steps of 1 unit, can be injected. Insulin labels must Toujeo is not the insulin of choice for the treatment of diabetic ketoacidosis. Toujeo. All insulins, including Novolin R, cause a shift in potassium from the extracellular to Toujeo may have additional side effects including swelling, weight gain, low potassium, and injection site reactions which may include change in fat tissue, skin thickening, redness, swelling, and itching. Bridgewater, NJ: Sanofi-Aventis U. 3% of the population) have diabetes with total medical costs estimated to be 2. Development timeline for Toujeo SoloStar. ANNOUNCER: These instructions do not replace the guidance of your doctor or the instructions for use that accompanies the Toujeo ® SoloStar ® (insulin glargine) injection 300 Units/mL or Toujeo ® Max SoloStar ® pens. However, it is important to consider how species differences in pathophysiology, management practices and goals, Toujeo [package insert]. LLC; 2015 Feb. (2021). LYUMJEV™ is indicated to improve glycemic control in HIGHLIGHTS OF PRESCRIBING INFORMATION Known serious hypersensitivity to mounjaro. This TOUJEO is a long- acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus (1) Limitations of Use: Not recommended for treating diabetic ketoacidosis. europa. Data sources. 2, 0. Introduction. Doing so can result in multiple problems, including damage to the pen that may prevent correct administration of future doses, introduction of air into the insulin pens that can result in underdosing of subsequent TOUJEO is available in 2 single-patient-use prefilled pens: The TOUJEO SoloStar prefilled pen contains 450 units of insulin glargine. ; 2015 Feb. The U-200 pen delivers the same dose label - Food and Drug Administration Toujeo is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus. 5 mL: 300 units/mL: 450 units: 80 units: 1 unit: 0024-5869-03: 3 pens/pack: Max SoloStar disposable prefilled pen: 3 mL : 300 units/mL: 900 units: 160 units: 2 units: 0024-5871-02: 2 pens/pack: Needles are not included in the packs of TOUJEO SoloStar or TOUJEO Max SoloStar disposable prefilled pen. TOUJEO contains 300 units/mL insulin glargine TOUJEO is available in 2 single-patient-use prefilled pens: TOUJEO SoloStar contains 450 units of TOUJEO U-300. Vials, pens. BD (such as BD Ultra Toujeo® SoloStar® Welcome Pack For Diabetes MAT-MY-2200281 (V1. 0001 vs glipizide + metformin. Medicines that interact with Toujeo Max Solostar may either B. 2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen Changes in Insulin Regimen Including Changes to Administration Site Changes in an insulin TOUJEO ™ SoloSTAR® Insulin glargine (rDNA origin) AND PACKAGING. Policy # 00728 Table 1 includes currently available insulins and Table 2 is the package insert references for primary care providers. A survey was conducted to assess the prevalence of insulin pen use and current utilization trends in the Sanofi US, Inc. 5 ml in 1 syringe (0024-5869-01) of Toujeo, a human prescription drug labeled by Sanofi-aventis U. Princeton (NJ): Novo Nordisk Inc. A comprehensive literature search was conducted using MEDLINE with the key terms: insulin glargine 300, Toujeo, Gla-300, and EDITION for clinical trial data. ! If you do not follow all of these instructions, you may get too much or too little insulin leading to a potentially serious hypo or poor control of your diabetes. See insulin dosing for more. Insulin glargine. Proper control of diabetes may also lessen your risk of a heart attack or stroke. inactive ingredients: see section 6. Humulin R U-100 is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. You may see air bubbles in the insulin — this is normal. Talk to TOUJEO. Specs. Before using Toujeo Solostar pre-filled pen (referred hereafter as “Toujeo”), the instructions for use included in the package leaflet must be read carefully. They may Toujeo [package insert]. Explore diabetes Explore obesity Explore rare bleeding Toujeo Max Solostar is a higher volume pen than Toujeo Solostar. You do not need to do any dose calculations. TOUJEO is available in 2 single-patient-use prefilled pens: TOUJEO SoloStar contains 450 units of TOUJEO U-300. In rabbits, early pregnancy loss and skeletal defects were seen at doses 0. If you are not sure whether you should start using this medicine, talk to your doctor. com. Always check insulin labels before administration. Bridgewater, NJ: sanofi-aventis US LLC; June 2022. TOUJEO ®SoloStar (Too-Jay-o) (insulin glargine injection) 1. Viatris and Biocon Biologics announce launch of interchangeable SEMGLEE (insulin glargine-yfgn) injection and insulin glargine (insulin glargine-yfgn) injection. • The dose selector of your NAME AND PRESENTATION: Toujeo 300 units/ml, solution for injection in a prefilled pen. Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular However, the package inserts for each of the insulin pens explicitly state that patients should not draw up insulin out of the pens using a syringe (3,6,7). Peak. 9 and 6. It delivers doses in 2-unit increments and can deliver up to 160 units in • Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts. Toujeo® is given In type 1 diabetes mellitus, Toujeo is to be used once- daily with meal-time insulin and must be combined with short-/rapid-acting insulin to cover mealtime insulin requirements. Preference was given to randomized controlled trials, pharmacody-namics, and pharmacokinetics studies. J, Sanofi-Aventis, 2015 [Google Scholar] 16. 2 units/kg once daily; Toujeo® may be administered at any time during the day; Toujeo® should be administered at the same time every day; Toujeo® is a basal insulin. , insulin strength, manufacturer, type, injection site, or method of administration) under close medical supervision with PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) – 1986 The medicine is dispensed with a doctor’s prescription only Toujeo Solution for subcutaneous injection in DoubleStar pen Active ingredient: Each pre-filled DoubleStar pen contains 300 units/ml of insulin glargine. Instruct patients to check insulin labels before injection. BHD. It is approved for use in patients with type 1 or type 2 diabetes. Important Safety Information for Toujeo U-300 (insulin glargine) injection SoloStar and Toujeo Max SoloStar. Insulin glargine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. It delivers doses in 2-unit increments and can deliver up to 160 units in a single injection. The remainder of the total daily insulin dose should be given as a short-acting insulin and divided between each daily meal. It has been developed and funded by Sanofi to provide additional support that complements the advice from your healthcare professional. This medicine may make you dizzy or drowsy. , insulin strength, manufacturer, type, injection site or method of administration) under for use included in the package leaflet must be read carefully. The Toujeo pen can provide 80 units per dose, but with less liquid than Lantus. Heidenreich PA, Bozkurt B, Aguilar D, et al; Writing Committee Members. Bridgewater, NJ: Sanofi-Aventis. With Toujeo TOUJEO (insulin glargine) injection is a sterile, clear and colorless solution for subcutaneous injection. Once-daily NPH insulin to once-daily Insulin Glargine, the recommended starting Insulin Glargine dosage is the same as the dosage of NPH that is being discontinued. It should not be given by IV, IM, or via an infusion pump. Humalog ® Mix 75/25 [package insert]. • Each Toujeo® DoubleStar® prefilled pen contains 900 units in total and a dose of 2-160 units can be given in one injection (doses are selected in steps of 2 units at a time). Onset. Talk to your doctor about proper injection technique and follow instructions in the Instruction Leaflet that comes with your Toujeo SoloStar or Toujeo Max SoloStar pen. ) If chickenpox develops, treatment with antiviral agents may be considered. Do not give Toujeo Max SoloStar to a child or adolescent. If you do not follow all instructions, you may receive too much or too little insulin. The use of insulin pens in the inpatient setting has continued to be a controversial decision. Talk to Reference ID: 4131552 - Food and Drug Administration xigduo xr. Dosing guide for Toujeo® (insulin glargine) injection 300 Units/mL and Toujeo Max SoloStar®. Insulin pens provide several advantages, but given significant reports of medication errors, several organizations have issued alerts to caution users about safety concerns. PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986 The medicine is dispensed with a doctor’s prescription only Toujeo Solution for Subcutaneous injection Active ingredient: Each SoloStar pre-filled injection pen contains 300 units/ml of insulin glargine. Purpose: The purpose of this article is to educate nurse practitioners about the role of Toujeo®, insulin glargine U-300 (Gla-300), which is a new option for the treatment of diabetes mellitus. (2023). In clinical trials both were found comparable to Lantus (insulin glargine) and Levemir (insulin detemir [rDNA origin] injection), with regard to lowering A1c; both may also be associated with lower Insulin Glargine U-300 (Toujeo): A series of clinical trials (TABLE 2) compared concentrated insulin glargine U-300 with U-100 (Lantus). 3)]. Toujeo Solostar must be given by subcutaneous (under the skin) injection. 2 to 1 units/kg/day, with some patients requiring ≥3 units/kg/day. Humalog ® Mix 50/50 [package insert]. Riddle MC, Yki-Järvinen H, Bolli GB, et al. Login / Register PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) – 1986 The medicine is dispensed with a doctor’s prescription only Toujeo Solution for subcutaneous injection in DoubleStar pen Active ingredient: Each pre-filled DoubleStar pen contains 300 units/ml of insulin glargine. Starting Dosage. How does Toujeo work? Diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose. Your dose needs may change if you switch to a different brand, strength, or form of this medicine. LLC. Contents of the pack and other information 1. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, Toujeo, INN-insulin glargine - ema. Basaglar [package insert]. 1) • Risk of seizure may be minimized by adhering to the • Once-daily TOUJEO (insulin glargine 300 units/mL) to once-daily LANTUS (100 units/mL), the recommended starting LANTUS dosage is 80% of theTOUJEO dosage that is being discontinued. How to store Toujeo 6. Glargine U-300 contains three times the amount of insulin per milliliter as glargine U-100. How to inject. Toujeo is available in prefilled pens for self-injection. Once-daily TOUJEO (insulin glargine 300 units/mL) to once-daily Insulin Glargine (100 units/mL), the recommended starting Insulin Glargine dosage is 80% of the TOUJEO dosage that is being discontinued. Humalog Mix50/50, a mixture of 50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin), is indicated in the treatment of patients with diabetes mellitus for the control of This label may not be the latest approved by FDA. Hyperglycemia or hypoglycemia with changes in insulin regimen: Make changes to a patient’s FIASP® (insulin aspart) injection 100 U/mL 2 Risk Factors for Hypoglycemia The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose Toujeo 300 yksikköä/ml injektioneste, liuos esitäytetyssä kynässä (SoloStar) KÄYTTÖOHJEET. Diabetes Other Therapy Areas. This allows higher dosages to be given more easily. Consider other antidiabetic therapies in patients with a history of pancreatitis. The TOUJEO Max SoloStar prefilled pen contains 900 units of insulin glargine. As for all medicines, data on the use of Toujeo are continuously monitored. Before injecting Toujeo. 4)(insulin glargine injection) U-300, Toujeo® exhibits a more constant and prolonged glucose-lowering profile than LANTUS. Limitations of Use: Toujeo is not recommended for the treatment of diabetic ketoacidosis. Please see full Important Safety Toujeo SoloStar (insulin glargine [rDNA origin] is a once-daily long-acting basal insulin used to improve glycemic control in adults with type 1 and type 2 diabetes. The indication in our approval letter dated February 25, 2015, should have read: Toujeo is a long- acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. cOpened (in-use) SoloSTAR ® devices must be discarded 4 weeks (Lantus ®) or 8 weeks (Toujeo ®) after being opened. All There are three pens in a box of Toujeo Solostar. Viatris Inc. 2. The U-200 pen delivers the same dose The dosage of Toujeo Solostar in elderly people should be conservative. Doing so can result in multiple problems, including damage to the pen that may prevent correct administration of future doses, introduction of air into the insulin pens that can result in underdosing of subsequent Toujeo may have additional side effects including swelling, weight gain, low potassium, and injection site reactions which may include change in fat tissue, skin thickening, redness, swelling, and itching. Many diabetic therapies available in human medicine or on the horizon could hold promise in the management of small animal diabetes. These products contain a greater amount of insulin glargine in a smaller amount of liquid, making larger doses more manageable. Humulin ® Certain drugs tend to produce hyperglycemia and may lead to loss of control. , insulin strength, manufacturer, type, injection site, or method of administration) under close medical Toujeo® Max Solostar® is a 900 Unit pen with concentrated insulin, that can fit up to 3X more insulin in the same-size standard pen, which may mean fewer pens, injections, refills, and co-pays. Eligibility criteria consisted of articles that were published in English and available in full text. 1 Type 2 Diabetes Mellitus FARXIGA (dapagliflozin) is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. †Eligibility Restrictions & Offer Terms: TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pens must never be shared between patients, even if the needle is changed. 3 . During episodes of hypoglycemia (see WARNINGS AND PRECAUTIONS). In rat studies, insulin glulusine had no effects on embryo or fetal development at doses 10 times the human dose. Advise patients who have repeatedly injected into areas of lipodystrophy or Never Share a LEVEMIR FlexPen, insulin syringe, or needle between patients, even if the needle is changed (). Download transcript. Registration No : MAL16075050AZ. MAX AMY: Then with the needle you’re going to peel off the protective seal and screw the needle onto the pen, until it feels fixed. MAX AMY: Then you’re going to remove the outer cap and put that somewhere safe. Place your order NOW and enjoy FREESHIPPING*, use code If you're looking for information about the Toujeo insulin pen, then this video is perfect for you! In this video, we'll show you how to use the Toujeo insul. PAST AMY: Keep the outer cap, toss the inner, got it. Utah Academy of Family Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Email this page Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Your Personal Message . One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial If changing patients from once-daily TOUJEO (insulin glargine) 300 units/mL to once-daily Insulin glargine, the recommended initial Insulin glargine dose is 80% of the TOUJEO dose that is being discontinued. Subcutaneous use 3 pens 300 1 step = 2 units 900 units per pen 1 hour DoubleStar™ Take your new Toujeo® DoubleStarTM pen out of the fridge at least 1 hour before you use it for the first time. If the product appears cloudy, discoloured or contains particles, or if the injection pen appears damaged. People who have vision problems should not use the Toujeo SoloStar or Toujeo Max SoloStar pen without help from a person 3 . The recommended starting dose of TOUJEO in insulin-naive patients with type 1 diabetes is approximately one-third to one-half of the total daily insulin dose. 1 Toujeo® (insulin glargine injection) U-300 Fact Sheet Last Updated: March 2015 About Toujeo® Toujeo® (insulin glargine injection) U-300 is a once-daily, long-acting basal insulin to improve glycemic control in adults living with type 1 and type 2 diabetes. Availability. , insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood What is Toujeo U-300 (insulin glargine) injection 300 Units/mL? Prescription Toujeo is a long-acting man-made insulin used to control high blood sugar in adults and children who are 6 years of age and older with diabetes mellitus. In type 1 diabetes patients treated with IV insulin, consider the longer onset of action of TOUJEO before stopping IV insulin. 2015;11(8):1193-1201. S. TOUJEO contains 300 units/mL insulin glargine TOUJEO prescription and dosage information for physicians and health care professionals. Prep With clean hands, remove pen cap and check to make sure insulin is clear and colorless without particles. (5. ()Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Make changes to a patient's insulin regimen (e. What Toujeo is and what it is used for 2. The “U300” is highlighted in honey gold on the label. 14. The product's dosage form is injection, solution and is administered via subcutaneous form. Hypokalemia . The full glucose discontinued. Initiation of Toujeo ® Patients with type 1 diabetes mellitus . Manufacturer : Sanofi-Aventis Deutschland GmbH. • Refer to the continuous subcutaneous insulin infusion pump user manual to see if HUMALOG can be used with the insulin pump. − . 2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen Changes in Insulin Regimen Including Changes to Administration Site Changes in an insulin TOUJEO is not recommended for the treatment of diabetic ketoacidosis. Lue tämä ensin. Do not drive or INDICATIONS AND USAGE . All Toujeo may have additional side effects including swelling, weight gain, low potassium, and injection site reactions which may include change in fat tissue, skin thickening, redness, swelling, and itching. To reduce the risk of hypoglycemia, patients who are changing their basal insulin regimen from an insulin regimen with once daily insulin glargine 300 units/ml to a once daily regimen with Lantus should reduce their dose by approximately 20%. LLC; 2014 Humalog® [package insert]. As Some package inserts may say that Toujeo needs to be discarded after 42 days; however, this is not what the current prescribing information says. Vials of insulin are available for long-, intermediate-, short-, rapid-, and ultra-rapid-acting insulins, as well as premixed insulin products and the concentrated U-500 (500 units/mL) Toujeo SoloStar and Toujeo Max SoloStar are single-patient-use prefilled insulin pens. Blood glucose monitoring is recommended for all patients with diabetes. . • The Insulin label should always be checked before each injection to avoid PARIS, Feb. Toujeo is a long-acting form of man-made insulin (insulin glargine) that may be used for the treatment of high blood sugar levels in adults and children 6 years and older with diabetes mellitus. The Toujeo Max pen contains 900 units of insulin compared with 450 units for the Toujeo pen, although the concentration for both remains the same, 300 units/mL. Name. Includes: indications, dosage, adverse reactions and pharmacology. • Once-daily NPH insulin to once-daily LANTUS, the recommended starting LANTUS dosage is the same as the dosage of NPH that is being discontinued. Learn about its dosage, administration, contraindications, precautions, warnings, adverse reactions Dosage and Administration: Toujeo is administered subcutaneously, by injection into the abdominal wall, the deltoid or the thigh, once daily, at any time of the day, preferably at the Toujeo is a basal insulin for once-daily administration at any time of the day, preferably at the same time every day. In the United States alone, approximately 29. Once Toujeo has been left out of the refrigerator for more than 20 or 30 minutes, it should not be put back into TOUJEO ®SoloStar (Too-Jay-o) (insulin glargine injection) 1. (Hyperglycemia or hypoglycemia with changes in insulin regimen: Make changes to a patient's insulin regimen (e. g. See full prescribing information for TOUJEO. Toujeo® contains the same active ingredient, insulin glargine, as LANTUS. Do not use it if you had an allergic reaction to insulin glargine, or during episodes of hypoglycemia (low blood sugar). ()Hypoglycemia: May be life-threatening. TOUJEO contains 300 units/mL insulin glargine Toujeo is not the insulin of choice for the treatment of diabetic ketoacidosis. Plainsboro, New Jersey. TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pens must never be shared between patients, even if the needle is changed. Toujeo® received approval from the U. (Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Make changes to a patient’s insulin regimen (e. Monitor blood glucose and increase monitoring frequency with changes to Throw away any opened Toujeo® Max SoloStar® or SoloStar® pen after 56 days. In most clinical situations, insulin is the preferred method for hyperglycemia management in the inpatient setting (). eu hlqlqjdu po Toujeo 300 units/ml Solution for Injection in Pre-Filled Pen. 2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen Changes in Insulin Regimen Including Changes to Administration Site Changes in an insulin Glargine U-300, sold under the trade name Toujeo, is a long-acting insulin for subcutaneous injection, containing 300 units/mL of insulin glargine. For current labeling Metabolism Toujeo (insulin glargine 300 units/mL) is a basal insulin for once-daily subcutaneous administration at any time of the day, preferably at the same time every day. Toujeo 300 units/ml SoloStar solution for injection in a pre-filled pen. Llc. Plainsboro, NJ: Novo Nordisk Inc. (Changes in Insulin Regimen: Carry out under close medical supervision and increase frequency of blood glucose monitoring. Expert Opin Drug Metab Toxicol. This is a modified insulin, very similar to This package insert is con tinually updated: Please re ad carefully before using a new pack. Lane W, Bailey TS, Gerety G, et al. (2. Pharmacology, adverse reactions, warnings, and TOUJEOside effects. 5. This drug has been classified in the anatomical therapeutic chemical (ATC) Packaging Content (concentration) Pack size EU/1/00/133/033 Toujeo 300 units/ml Solution for injection Subcutaneous use cartridge (glass) in pre-filled pen (SoloStar) 1. TOUJEO is not recommended for the treatment of diabetic Toujeo is a long-acting insulin for the treatment of diabetes mellitus in adults and children. When switching from insulin glargine 100 units/ml to Toujeo, this can be done on a unit-to-unit basis, but TOUJEO- insulin glargine injection, Package size; SoloStar single-patient-use prefilled pen: 1. For single patient use only. Switch from other basal Purpose: The purpose of this article is to educate nurse practitioners about the role of Toujeo®, insulin glargine U-300 (Gla-300), which is a new option for the treatment of diabetes mellitus. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024. fhpjxaj xkwbmmtp adojxg efi cyvp gzpupa nozjp vxph hkx wnzhh